Sorrento Tech (NASDAQ: ROKA) and Anacor Pharmaceuticals (NASDAQ:ANAC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.
This is a summary of current recommendations for Sorrento Tech and Anacor Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
48.1% of Sorrento Tech shares are held by institutional investors. 29.2% of Sorrento Tech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Sorrento Tech and Anacor Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Sorrento Tech has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Anacor Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sorrento Tech and Anacor Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sorrento Tech||$7.24 million||0.45||-$30.78 million||($8.79)||-0.07|
Anacor Pharmaceuticals has lower revenue, but higher earnings than Sorrento Tech. Anacor Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Tech, indicating that it is currently the more affordable of the two stocks.
Sorrento Tech beats Anacor Pharmaceuticals on 8 of the 9 factors compared between the two stocks.
About Sorrento Tech
Sorrento Tech, Inc., formerly Roka Bioscience, Inc., is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
About Anacor Pharmaceuticals
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
Receive News & Ratings for Sorrento Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Tech and related companies with MarketBeat.com's FREE daily email newsletter.